• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Shineco Inc.

    8/26/22 12:36:13 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    SC 13D 1 sc13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a)

     

    Under the Securities Exchange Act of 1934*

     

    Shineco, Inc.

     

    (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $0.001 PER SHARE

     

    (Title of Class of Securities)

     

    824567309

     

    (CUSIP Number)

     

    Shanchun Huang

    Flat 111 Coleherne Court

    Old Brompton Road London, UK SW5 0ED

    Telephone: +447999 688888

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 26, 2022

     

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

    1          The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 824567309

    13D 

     

     

    1

     

    NAME OF REPORTING PERSON

     

    Shanchun Huang

     

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐
        (b) ☐

     

    3

     

    SEC USE ONLY

     

     

    4

     

    SOURCE OF FUNDS (SEE INSTRUCTIONS) PF

     

     

    5

     

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

    ☐

     

    6

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Malta

     

     

    NUMBER OF

    SHARES

    7

     

     

    SOLE VOTING POWER

     

    2,489,277

     

    BENEFICIALLY

    OWNED BY

    8

     

    SHARED VOTING POWER

    n/a

     

    EACH

    REPORTING

    9

     

     

    SOLE DISPOSITIVE POWER

     

    2,489,277

     

    PERSON WITH

    10

     

     

    SHARED DISPOSITIVE POWER

     

    n/a

     

    11

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,489,277

     

    12

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

    CERTAIN SHARES (SEE INSTRUCTIONS)                                                                                                              ☐

     

    13

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

        15.18% (1)

     

    14

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

        IN

     

    (1) This percentage is calculated based upon 16,397,356 shares of the Issuer’s common stock issued and outstanding as of August 24, 2022

     

     

    CUSIP No. 824567309

    13D 

     

    Item 1. Security and Issuer.

     

    This Schedule 13D relates to the common stock par value $0.001 per share (the “Common Stock”) of Shineco, Inc., a Delaware Corporation (the “Issuer”). The address of the principal executive offices of the Issuer is Room 3310, North Tower, Zhengda Center, No. 20, Jinhe East Road, Chaoyang District, Beijing People’s Republic of China 100020.

     

    Item 2. Identity and Background.

     

    This statement is filed by Shanchun Huang, a Malta citizen (the “Reporting Person”).

     

    The principal mailing address of the Reporting Person is Flat 111 Coleherne Court, Old Brompton Road London SW5 0ED.

     

    None of the entities or persons identified in this Item 2 has during the past five years been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor been a party to a civil proceeding of a judicial or administrative body of competent judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    All shares were purchased with the Reporting Person’s personal funds.

     

    Item 4. Purpose of Transaction.

     

    On June 13, 2022, the Issuer entered into a certain stock purchase agreement (the “SPA”) with the Reporting Person, pursuant to which the Issuer sold and issued to the Reporting Person 1,082,250 shares of Common Stock at a price of $ 2.12 per share on July 26, 2022.

     

    On August 11, 2022, the Issuer entered into a securities purchase agreement (the “Purchase Agreement”) with the Reporting Person. In connection with the Purchase Agreement, the Reporting Person purchased from the Issuer a total of 533,448 shares of Issuer’s Common Stock at a per share purchase price of $0.915 on August 17, 2022.

     

    The Reporting Person acquired all of his shares of the Issuer’s Common Stock for investment purposes. The Reporting Person believes the securities of the Issuer represent an attractive investment opportunity.

     

    The Reporting Person has had and anticipates having further discussions with officers of the Issuer in connection with the Reporting Person’s investment in the Issuer. The topics of these conversations will cover a range of issues, including those relating to the business , management, operations, capital allocation, asset allocation, capital and corporate structure, distribution policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation, and corporate governance. The Reporting Person may also communicate with other stockholders or interested parties, such as industry analysts, existing or potential strategic partners or competitors, investment professionals, and other investors. The Reporting Person may at any time reconsider and change his intentions relating to the foregoing. The Reporting Person may also take one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D and may discuss such actions with the Issuer’s management, other shareholders of the Issuer, and other interested parties, such as those set out above.

     

     

    CUSIP No. 824567309

    13D 

     

    The Reporting Person intends to review his investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer’s financial positions and strategic direction, the outcome of the discussions and actions referenced above, actions taken by the board of directors, price levels of the Common Stock, other investment opportunities available to the Reporting Person, tax implications, conditions in the securities market and general economic and industry conditions, the Reporting Person may in the future take actions with respect to its investment position in the Issuer as it deems appropriate, including, without limitation, purchasing additional Common Stock or other instruments that are based upon or relate to the value of the Common Stock or the Issuer in the open market or otherwise, sales of some or all of its interests held by the Reporting Person, and/or engaging in hedging or similar transactions with respect to the Common Stock.

     

    Mr. Huang is an affiliate of the Issuer and will continue to take an active role in the Issuer’s management and strategic direction.

     

    Item 5. Interest in Securities of the Issuer.

     

    a)The Reporting Person owns an aggregate of 2,489,277 shares of the Issuer’s Common Stock. Based upon 16,397,356 shares of the Issuer’s common stock outstanding as of August 24, 2022, the shares of the Issuer’s Common Stock beneficially owned by the Reporting Person constitute approximately 15.18% of the Common Stock of the Issuer as calculated in accordance with Rule 13d-3(d)(1).
       
    b)Mr. Huang may be deemed to hold sole voting and dispositive power over 2,489,277 shares of common stock of the Issuer.
       
    c)To the best knowledge of the Reporting Person, except as set forth in this Schedule 13D, the Reporting Person has not effected any other transactions in any securities of the Issuer in the past 60 days.
       
    d)To the best knowledge of the Reporting Person, except as set forth in this Schedule 13D, no person other than the Reporting Person has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares of common stock reported in Item 5(a).
       
    e)Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Other than as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit

    Number

     

    Description

    10.1   Share Purchase Agreement dated June 13, 2022, by and between the Issuer and the Reporting Person (incorporated by reference to Exhibit 10.1 of the to the Issuer’s Current Report on Form 8-K, filed with the SEC on June 17, 2022).
    10.2   Securities Purchase Agreement dated August 11, 2022, by and between the Issuer and the Reporting Person (incorporated by reference to Exhibit 10.1 of the to the Issuer’s Current Report on Form 8-K, filed with the SEC on August 17, 2022).

     

     

    CUSIP No. 824567309

    13D 

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.

     

    August 26, 2022 /s/ Shanchun Huang
      Shanchun Huang

     

     

    Get the next $SISI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market

      BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement with Total World Marketing (Thailand) ("TWM"), pursuant to which TWM will be responsible for the promotion and sale of InfiniClone's molecular detection kits and InfiniClone's Purelix series health products in the Southea

      5/13/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

      Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re

      4/23/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Medical Device Company

      The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited ("Shineco Life Science"), a subsidiary of the Company, entered into a Stock Purchase Agreement ("SPA") with Yi Yang (the "Seller"), for 75% of an equity interest in FuWang (HK) International Company Limited ("FuWang Company"). The Seller is the current and only shareholder of FuWang Company, which specializes i

      3/25/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Shineco Inc.

      SC 13G/A - SHINECO, INC. (0001300734) (Subject)

      10/25/24 2:45:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Shineco Inc.

      SC 13D - SHINECO, INC. (0001300734) (Subject)

      7/12/24 5:28:03 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Shineco Inc.

      SC 13G - SHINECO, INC. (0001300734) (Subject)

      8/29/23 1:26:38 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    SEC Filings

    See more
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      4/23/25 9:00:37 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      3/20/25 2:30:26 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Shineco Inc.

      EFFECT - SHINECO, INC. (0001300734) (Filer)

      3/20/25 12:15:03 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

      3 - SHINECO, INC. (0001300734) (Issuer)

      4/24/25 4:05:15 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Yan Chi Keung

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Wang Xiaohui

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:16 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    See more
    • Future FinTech Announces the Appointment of Hu Li as the New CEO

      NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

      8/9/24 9:00:00 AM ET
      $FTFT
      $SISI
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces the Appointment of Two New Executive Officers

      BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

      11/17/23 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

      BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R

      2/1/22 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care